Dr Fabio Verzini (University of Perugia, IT) discusses the Valiant Navion IDE study - Investigational Device Exemption (IDE) study analysing the safety and efficacy of Valiant Navion in patients with TAA and PAU.
Why was the Valiant Navion study needed? (0:10)
What data has been presented at Veith? (0:45)
How does this compare to other TEVAR devices on the market? (1:22)
What patients is the Valiant Navion most suitable for? (2:00)
What further data from the Valiant Navion programme should be anticipated? (2:22)
Filmed by Radcliffe Vascular on site at VEITH 2018.